- Home
- GFAI vs INAB Comparison
GFAI vs INAB Comparison
Compare GFAI & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFAI
- INAB
- Stock Information
- Founded
- GFAI 2018
- INAB 2016
- Country
- GFAI Singapore
- INAB United States
- Employees
- GFAI N/A
- INAB N/A
- Industry
- GFAI Diversified Commercial Services
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- GFAI Consumer Discretionary
- INAB Health Care
- Exchange
- GFAI Nasdaq
- INAB Nasdaq
- Market Cap
- GFAI 12.5M
- INAB 24.0M
- IPO Year
- GFAI N/A
- INAB 2021
- Fundamental
- Price
- GFAI $1.09
- INAB $0.25
- Analyst Decision
- GFAI Strong Buy
- INAB Strong Buy
- Analyst Count
- GFAI 2
- INAB 3
- Target Price
- GFAI $6.75
- INAB $7.75
- AVG Volume (30 Days)
- GFAI 1.8M
- INAB 727.4K
- Earning Date
- GFAI 12-27-2024
- INAB 11-12-2024
- Dividend Yield
- GFAI N/A
- INAB N/A
- EPS Growth
- GFAI N/A
- INAB N/A
- EPS
- GFAI N/A
- INAB N/A
- Revenue
- GFAI $35,841,743.00
- INAB N/A
- Revenue This Year
- GFAI $0.37
- INAB N/A
- Revenue Next Year
- GFAI $5.60
- INAB N/A
- P/E Ratio
- GFAI N/A
- INAB N/A
- Revenue Growth
- GFAI 1.78
- INAB N/A
- 52 Week Low
- GFAI $0.94
- INAB $0.22
- 52 Week High
- GFAI $4.30
- INAB $1.93
- Technical
- Relative Strength Index (RSI)
- GFAI 42.23
- INAB 39.26
- Support Level
- GFAI $1.20
- INAB $0.28
- Resistance Level
- GFAI $1.35
- INAB $0.32
- Average True Range (ATR)
- GFAI 0.19
- INAB 0.03
- MACD
- GFAI -0.04
- INAB -0.01
- Stochastic Oscillator
- GFAI 18.74
- INAB 13.73
About GFAI Guardforce AI Co. Limited
Guardforce AI Co Ltd is a provider of cash solutions and cash handling services located in Thailand. The company engages in the cash logistics business, and its services include cash-in-transit, or CIT, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions (cash deposit management and express cash service). Its customers include local commercial banks, chain retailers, coin-manufacturing mints, and government authorities.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.